Replimune Group, Inc. presented primary analysis data from its IGNYTE clinical trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) on November 9, 2024. The oral presentation highlighted anti-tumor activity across all patient subgroups, with both injected and non-injected lesions demonstrating similar frequency, depth, duration, and kinetics of response.
Initial biomarker analyses showed increases in tumor CD8+ T cell and PD-L1 expression after dosing, alongside an induction of immune inflammatory gene signatures. These findings further support the intended mechanism of RP1 in combination with nivolumab, including its ability to induce a systemic anti-tumor immune response after progression on prior anti-PD1 therapy.
The IGNYTE trial cohort in anti-PD-1 failed melanoma included 140 patients, with a median follow-up of 15.4 months. RP1 combined with nivolumab maintained a well-tolerated safety profile, characterized predominantly by Grade 1-2 constitutional type adverse events, with a low incidence of Grade 3-4 events and no Grade 5 events reported.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.